Preliminary safety and efficacy of oral azacitidine (Oral-AZA) in patients (pts) with low-/Intermediate (Int)-risk myelodysplastic syndromes (MDS): Phase 2 results from the ASTREON trial.
Guillermo Garcia‐Manero(The University of Texas MD Anderson Cancer Center), Aristoteles Giagounidis(Marien Hospital Düsseldorf), Pierre Fenaux(Saint Louis University Hospital), Daniel L. Menezes(Bristol-Myers Squibb (Germany)), Thomas Prébet(Yale University), Takahiro Suzuki(Keio University), Matteo Della Porta(University of Milan), Mikkael A. Sekeres(University of Miami), Karen Yee(University Health Network), Francisca Hernández(Universitat de Miguel Hernández d'Elx), Carlos E. Vigil(Bristol-Myers Squibb (United States)), Ronit Barkalifa(Ben-Gurion University of the Negev), Joseph W. Burnett(Bristol-Myers Squibb (United States)), Valeria Santini(Azienda Ospedaliero-Universitaria Careggi), Jun He(Jiangnan University), Jerry Li(Bristol-Myers Squibb (United States)), Stefania Paolini(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Seo-Yeon Ahn(Chonnam National University Hwasun Hospital), Rami S. Komrokji(Moffitt Cancer Center)
Cited by 2
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
|Annals of Oncology|2020|1.5k